OZALIN® continues to receive marketing authorization approvals across EU
Zug, 2nd March 2020, Swiss company Primex Pharmaceuticals announces it has received international approval of the repeat use procedure for OZALIN® (ADV6209) involving the following 8 countries: Germany, Austria, Spain, Portugal, Ireland, Belgium, Greece, and Poland.This follows the decentralized regulatory approval and marketing authorization approval in France, UK, Italy, Netherlands, Finland, Norway, and Denmark at the end of 2018 for children from 6 months to 17 years for moderate sedation before therapeutic or diagnostic procedures, and as premedication prior to anaesthesia. OZALIN is